Patents by Inventor Sören Giese

Sören Giese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Patent number: 7655689
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: February 2, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Sören Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Patent number: 7517904
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: July 7, 2005
    Date of Patent: April 14, 2009
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Sören Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • Fused cyclic modulators of nuclear hormone receptor function
    Patent number: 7432267
    Abstract: Disclosed are compounds having the formula (I): including compounds of formulae (Ia) and (Ib): wherein G is an optionally substituted aryl or heterocyclo, L is an optional linker, M is a bond, O, CR7R7? or NR10, and M? is a bond or NR10, with the proviso that at least one of M or M? must be a bond; E is C=Z2, CR7CR7?, SO2, P?OR2, or P?OOR2; Z1 is O, S, NH, or NR6; A1 is CR7 or N; A2 is CR7 or N; Y is J-J?-J? where J is (CR7R7?)n and n=0?3, J? is a bond or O, S, S?O, SO2, NH, NR6, C?O, CO?O, NR1C?O, CR7R7?, C?CR8R8?, R2P?O, OPOOR2, OPO2, OSO2, C?N, NHNH, NHNR6, NR6NH, N?N, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo or aryl or substituted aryl, and J? is (CR7R7?)n and n=0?3; and W, Q, R2, R6, R7, R7?, R8, R8?, R9, R9?, and R10 are as defined in the specification and/or claims herein, to methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and to
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: October 7, 2008
    Assignee: Bristol-Myers Squibb Comapny
    Inventors: Mark E. Salvati, James Aaron Balog, Weifang Shan, Sören Giese, Lalgudi S. Harikrishnan
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Patent number: 7141578
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Grant
    Filed: October 25, 2004
    Date of Patent: November 28, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, James Aaron Balog, Dacia A. Pickering, Sören Giese, Aberra Fura, Wenying Li, Ramesh N. Patel, Ronald L. Hanson, Toomas Mitt, Jacques Y. Roberge, James R. Corte, Steven H. Spergel, Richard A. Rampulla, Raj N. Misra, Hai-Yun Xiao
  • Fused cyclic modulators of nuclear hormone receptor function
    Patent number: 7001911
    Abstract: The invention pertains to fused cyclic compounds having the formula, wherein G is an optionally substituted aryl or heterocyclo, L is an optional linker, M is a bond, O, CR7R7? or NR10, and M? is a bond or NR10, with the proviso that at least one of M or M? must be a bond; E is C?Z2, CR7CR7?, SO2, P?OR2, or P?OOR2; Z1 is O, S, NH, or NR6; Z2 is O, S, NH, or NR6; A1 is CR7 or N; A2 is CR7 or N; Y is J—J?—J? where J is (CR7R7?)n and n=0-3, J? is a bond or O, S, S?O, SO2, NH, NR6, C?O, OC?O, NR1C?O, CR7R7?, C?CR8R8?, R2P?O, OPOOR2, OPO2, OSO2, C?N, NHNH, NHNR6, NR6NH, N?N, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo or aryl or substituted aryl, and J? is (CR7R7?)n and n=0-3; W is CR7R7?—CR7R7?, CR8?CR8?, CR7R7?—C?O, NR9—CR7R7?, N?CR8, N?N, NR9—NR9?, cycloalkyl or substituted cycloalkyl, cycloalkenyl or substituted cycloalkenyl, heterocyclo or substituted heterocyclo, or aryl or substituted aryl; and O, R2, R6, R7, R7?, R8, R8?, R9, R9
    Type: Grant
    Filed: December 18, 2002
    Date of Patent: February 21, 2006
    Assignee: Bristol-Myers Squibb Company
    Inventors: Mark E. Salvati, James Aaron Balog, Weifang Shan, Sören Giese, Lalgudi S. Harikrishnan